rs376161880
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024079.5(ALG8):c.1090C>T(p.Arg364Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000824 in 1,614,060 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000092 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000081 ( 0 hom. )
Consequence
ALG8
NM_024079.5 stop_gained
NM_024079.5 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 6.76
Genes affected
ALG8 (HGNC:23161): (ALG8 alpha-1,3-glucosyltransferase) This gene encodes a member of the ALG6/ALG8 glucosyltransferase family. The encoded protein catalyzes the addition of the second glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation of proteins. Mutations in this gene have been associated with congenital disorder of glycosylation type Ih (CDG-Ih). Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
?
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 11-78106895-G-A is Pathogenic according to our data. Variant chr11-78106895-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 280116.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ALG8 | NM_024079.5 | c.1090C>T | p.Arg364Ter | stop_gained | 10/13 | ENST00000299626.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ALG8 | ENST00000299626.10 | c.1090C>T | p.Arg364Ter | stop_gained | 10/13 | 1 | NM_024079.5 | P3 |
Frequencies
GnomAD3 genomes ? AF: 0.0000920 AC: 14AN: 152108Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
14
AN:
152108
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251398Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135870
GnomAD3 exomes
AF:
AC:
14
AN:
251398
Hom.:
AF XY:
AC XY:
7
AN XY:
135870
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000814 AC: 119AN: 1461834Hom.: 0 Cov.: 31 AF XY: 0.0000756 AC XY: 55AN XY: 727218
GnomAD4 exome
AF:
AC:
119
AN:
1461834
Hom.:
Cov.:
31
AF XY:
AC XY:
55
AN XY:
727218
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000920 AC: 14AN: 152226Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74426
GnomAD4 genome
?
AF:
AC:
14
AN:
152226
Hom.:
Cov.:
32
AF XY:
AC XY:
9
AN XY:
74426
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
?
AF:
AC:
5
Asia WGS
AF:
AC:
1
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:17
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:8
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The ALG8 p.R364* variant was identified as a heterozygous variant in 3 of 102 individuals (frequency: 0.015) with polycystic liver disease (Besse_2017_PMID:28375157). In the compound heterozygous state, the variant has been reported in cases with congenital disorders of glycosylation Ih in probands who carried another pathogenic ALG8 variant (Vesela_2009_PMID:19688606; Hock_2015_PMID:26066342). The variant was identified in dbSNP (ID: rs376161880) and ClinVar (classified as pathogenic by GeneDx and EGL Genetics). The variant was identified in control databases in 18 of 282788 chromosomes at a frequency of 0.00006365 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 14 of 129120 chromosomes (freq: 0.000108), South Asian in 2 of 30616 chromosomes (freq: 0.000065), African in 1 of 24954 chromosomes (freq: 0.00004) and Latino in 1 of 35436 chromosomes (freq: 0.000028), but was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), or Other populations. The c.1090C>T variant leads to a premature stop codon at position 364 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the ALG8 gene are an established mechanism of disease in congenital disorders of glycosylation Ih and are the type of variant expected to cause the disorder when found in the homozygous or compound heterozygous state. Loss of function variants in the ALG8 gene may also contribute to autosomal dominant polycystic liver disease. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 06, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 16, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 27, 2023 | Observed in the heterozygous state in multiple unrelated individuals with polycystic liver disease (Besse et al., 2017); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 26066342, 22306853, 34426522, 31589614, 19688606, 28375157) - |
Polycystic liver disease 3 with or without kidney cysts Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Arkana Molecular Diagnostic Laboratory, Arkana Laboratories | Mar 23, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Zotz-Klimas Genetics Lab, MVZ Zotz Klimas | Oct 09, 2023 | - - |
ALG8 congenital disorder of glycosylation Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Oct 15, 2023 | This sequence change creates a premature translational stop signal (p.Arg364*) in the ALG8 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALG8 are known to be pathogenic (PMID: 19862844). This variant is present in population databases (rs376161880, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with congenital disorder of glycosylation type 1h (PMID: 19688606). ClinVar contains an entry for this variant (Variation ID: 280116). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
ALG8 congenital disorder of glycosylation;C4693472:Polycystic liver disease 3 with or without kidney cysts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 18, 2020 | The c.1090C>T (p.R364*) alteration, located in exon 10 (coding exon 10) of the ALG8 gene, consists of a C to T substitution at nucleotide position 1090. This changes the amino acid from an arginine (R) to a stop codon at amino acid position 364. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from the Genome Aggregation Database (gnomAD) database, the ALG8 c.1090C>T alteration was observed in 0.01% (18/282788) of total alleles studied, with a frequency of 0.01% (14/129120) in the European (non-Finnish) subpopulation. This alteration has been detected with another mutation in patients with clinical and biochemical features consistent with congenital disorder of glycosylation type Ih, and parental testing confirmed in trans in one patient (Vesela, 2009; Höck, 2015). This alteration has also been detected in the heterozygous state in three unrelated patients with polycystic liver disease with or without renal cysts (Besse, 2017); however, this disease does not currently meet published gene-disease clinical validity criteria for this gene (Smith, 2017). Based on the available evidence, this alteration is classified as pathogenic. - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Mar 11, 2021 | ACMG classification criteria: PVS1, PS4, PM2, PM3 - |
Autosomal dominant polycystic liver disease Pathogenic:1
Pathogenic, no assertion criteria provided | research | Laboratory of Gastroenterology and Hepatology, Radboud University Medical Center | Jun 08, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Pathogenic
Dann
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at